{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:05:50Z","timestamp":1771052750158,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":836,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Eldred Foundation"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study was performed to determine the ability to escalate drug doses in a 15-week CHOP protocol in dogs with multicentric lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>We hypothesized that at least 50% of dogs could successfully be escalated in at least 1 drug. Secondary aims were to establish objective response rate (ORR), progression-free interval (PFI), and overall survival time (OST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Thirty dogs with newly diagnosed multicentric lymphoma were prospectively treated with a 15-week CHOP protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective cohort study. Drug doses that did not cause dose-limiting adverse effects (AEs) were increased using a standardized escalation protocol. AEs and response were assessed using VCOG criteria. Serial blood samples were collected after the first dose of each drug for pharmacokinetic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 23 dogs with the opportunity to dose escalate, at least 1 drug was successfully escalated in 18 (78%). Vincristine was successfully escalated to 0.8\u2009mg\/m2 or higher in 11 dogs, cyclophosphamide to 300\u2009mg\/m2 or higher in 16 dogs, and doxorubicin to 35\u2009mg\/m2 or 1.4\u2009mg\/kg or higher in 9 dogs. Three of the 23 dogs (13%) were hospitalized at least once because of drug-induced AEs. Neutropenia was the most common dose-limiting toxicosis for all drugs. Peak doxorubicin concentrations were significantly lower in dogs where doxorubicin was successfully escalated. The objective response rate was 100%. The median progression free interval was 171\u2009days. The median overall survival time was 254\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Drugs in the CHOP protocol can often be escalated safely with manageable AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16875","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T04:38:07Z","timestamp":1696394287000},"page":"2402-2409","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3046-5127","authenticated-orcid":false,"given":"Jacob M.","family":"Siewert","sequence":"first","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, Colorado,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Gustafson","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, Colorado,","place":["USA"]},{"name":"University of Colorado Comprehensive Cancer Center , Aurora, Colorado,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-2246","authenticated-orcid":false,"given":"Kristen M.","family":"Weishaar","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, Colorado,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie M.","family":"Galloway","sequence":"additional","affiliation":[{"name":"Colorado Animal Specialty & Emergency , Boulder, Colorado,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7767","authenticated-orcid":false,"given":"Douglas H.","family":"Thamm","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, Colorado,","place":["USA"]},{"name":"University of Colorado Comprehensive Cancer Center , Aurora, Colorado,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"2026021401271644700_jvim16875-bib-0001","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026021401271644700_jvim16875-bib-0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1939-1676.1993.tb01021.x","article-title":"Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma","volume":"7","author":"Keller","year":"1993","journal-title":"J Vet Intern Med"},{"key":"2026021401271644700_jvim16875-bib-0003","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/vco.12163","article-title":"Retrospective analysis for treatment of na\u00efve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol","volume":"14","author":"Curran","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"2026021401271644700_jvim16875-bib-0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.tvjl.2015.04.032","article-title":"Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma","volume":"205","author":"Wang","year":"2015","journal-title":"Vet J"},{"key":"2026021401271644700_jvim16875-bib-0005","first-page":"196","article-title":"Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases","volume":"8","author":"Sorenmo","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"2026021401271644700_jvim16875-bib-0006","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1939-1676.2000.tb02224.x","article-title":"Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"14","author":"Chun","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026021401271644700_jvim16875-bib-0007","article-title":"TNM classification of tumors in domestic animals","author":"Owen","year":"1980"},{"key":"2026021401271644700_jvim16875-bib-0008","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1476-5829.2012.00324.x","article-title":"Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma","volume":"11","author":"Burton","year":"2013","journal-title":"Vet Comp Oncol"},{"key":"2026021401271644700_jvim16875-bib-0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2014a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"2026021401271644700_jvim16875-bib-0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/vco.283","article-title":"Veterinary Cooperative Oncology Group\u2014common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","author":"VCOG","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"2026021401271644700_jvim16875-bib-0011","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/vco.12455","article-title":"Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers","volume":"17","author":"Wittenburg","year":"2019","journal-title":"Vet Comp Oncol"},{"key":"2026021401271644700_jvim16875-bib-0012","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1939-1676.2011.0730.x","article-title":"Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma","volume":"25","author":"Warry","year":"2011","journal-title":"J Vet Intern Med"},{"key":"2026021401271644700_jvim16875-bib-0013","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1476-5829.2012.00340.x","article-title":"Development of a limited-sampling model for prediction of doxorubicin exposure in dogs","volume":"12","author":"Wittenburg","year":"2014","journal-title":"Vet Comp Oncol"},{"key":"2026021401271644700_jvim16875-bib-0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/1097-0142(19880201)61:3<451::AID-CNCR2820610308>3.0.CO;2-G","article-title":"Cyclophosphamide-induced hemorrhagic cystitis: a review of 100 patients","volume":"61","author":"Stillwell","year":"1988","journal-title":"Cancer"},{"key":"2026021401271644700_jvim16875-bib-0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/vco.12009","article-title":"Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case-control study","volume":"12","author":"Gaeta","year":"2014","journal-title":"Vet Comp Oncol"},{"key":"2026021401271644700_jvim16875-bib-0016","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2460\/javma.243.7.1025","article-title":"Incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for three days without concurrent furosemide as part of a chemotherapeutic treatment for lymphoma: 57 cases (2007-2012)","volume":"243","author":"Best","year":"2013","journal-title":"J Am Vet Med Assoc"},{"key":"2026021401271644700_jvim16875-bib-0017","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2460\/ajvr.1994.55.11.1587","article-title":"Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs","volume":"55","author":"Arrington","year":"1994","journal-title":"Am J Vet Res"},{"key":"2026021401271644700_jvim16875-bib-0018","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s11095-010-0363-8","article-title":"Assessment of pharmacologic area under the curve when baselines are variable","volume":"28","author":"Scheff","year":"2011","journal-title":"Pharm Res"},{"key":"2026021401271644700_jvim16875-bib-0019","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/clpt.1993.69","article-title":"Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer","volume":"53","author":"Piscitelli","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"2026021401271644700_jvim16875-bib-0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.1989.39","article-title":"Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin","volume":"45","author":"Ackland","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"2026021401271644700_jvim16875-bib-0021","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1939-1676.2005.tb02753.x","article-title":"Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?","volume":"19","author":"MacDonald","year":"2005","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/6\/2402\/66895697\/jvim16875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/6\/2402\/66895697\/jvim16875.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:27:29Z","timestamp":1771050449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/37\/6\/2402\/8483294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16875","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"2023-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}